These clearly verify the efficacy of VNLG/124, sunitinib, and linifanib in the treatment of HCC, and when NLRP3 is mutated, the sensitivity may be enhanced in the high-risk group of patients with low NLRP3 expression, thus bringing better clinical benefits. Here, NLRP3 is linked to hepatocellular carcinoma.